2. Pharmaceutical and health biotechnologies
From cancer to emerging infections, biotech is redefining how we prevent, diagnose, and treat disease.
- Antibodies and therapeutic proteins
- Gene and cellular therapies
- Genomics
- Glycomics
- Medical technologies
- Medicinal chemistry
- Metabolomics
- Microbiomes
- Molecular modelling and recognition
- Natural products
- Regenerative medicine
- Small molecule drug discovery and development
- Tissue engineering
- Vaccines
Track chair
Isabelle Rivière
Director, Cell Therapy and Cell Engineering Facility
Memorial Sloan Kettering Cancer Centre
Isabelle Rivière biography
Dr Rivière received her Ph.D. in Cellular and Molecular Biology from the University of Paris. She initiated her graduate studies at the Institut Curie in Paris and completed her thesis in the laboratory of Dr. Mulligan at the Whitehead Institute in Cambridge, MA. During this time, she developed novel retroviral vectors for in vivo long-term expression of transgenes in hematopoietic cells using MFG/SFG-based retroviral vectors that are widely used in clinical studies for the treatment of genetic and acquired disorders.
She subsequently worked as a post-doctoral fellow in the laboratory of Dr. Littman at New York University, NY. Dr. Rivière joined the faculty of Memorial Sloan-Kettering Cancer Center in 1999. She is currently the Director of the Michael G. Harris Cell Therapy and Cell Engineering Facility where she investigates the genetic modification of hematopoietic cells to increase or retarget the immune response against tumors.
Keynote speakers
Development of a recombinant Ebola virus vaccine (Adenovirus type 5 vector)
Helen Huihua Mao
Co-Founder and Executive Vice-President, Quality Assurance and Regulatory Affairs
CanSino Biologics Inc
Tianjin,China
Development of pluripotent stem cell-based therapies for geographic atrophy
Jane Lebkowski
President of R&D
Regenerative Patch Technologies
Portola Valley, United States
Invited speakers
Development of stem cell expanding molecules
Anne Marinier
Principal Investigator and Director of Medicinal Chemistry
Institute for Research in Immunology and Cancer, Université de Montréal
Montréal, Canada
CRISPR/Cas9 technology may be used to correct genes responsible for several monogenic hereditary diseases
Jacques Tremblay
Professor
Université de Laval
Québec, Canada
DNA nanostructures for cellular administration of therapeutic agents
Hanadi Sleiman
Canada Research Chair in DNA Nanoscience
Department of Chemistry, McGill University
Montréal, Canada
Changing the paradigms of drug delivery to the eye
Heather Sheardown
Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery Systems
McMaster University
Hamilton, Canada
Enhancing insect cells as a cell culture platform by improving control over protein expression
Marc Aucoin
Associate Professor, Department of Chemical Engineering
University of Waterloo
Waterloo, Canada
Bacteria making a meal of pharmaceuticals
Philippe Corvini
Head of the Institute for Ecopreneurship
University of Applied Sciences and Arts Northwestern Switzerland
Muttenz, Switzerland
Design and development of asfotase alfa, the first bone-targeted enzyme replacement therapy
Philippe Crine
Chief operating officer
PreciThera
Montreal, Canada
New trends in nanoparticles syntheses and applications
René Roy
Canada Research Chair in Therapeutic Chemistry
Director, Pharmaqam
Department of Chemistry, Université du Québec à Montréal
Montréal, Canada
Therapeutic antibody discovery: when the power of nature meets technology
Véronique Lecault
Co-Founder
AbCellera
Vancouver, Canada
- Date modified: